Steve Bryson, PhD, science writer —

Steve holds a PhD in biochemistry from the Faculty of Medicine at the University of Toronto, Canada. As a medical scientist for 18 years, he worked in both academia and industry, where his research focused on the discovery of new vaccines and medicines to treat inflammatory disorders and infectious diseases. Steve is a published author in multiple peer-reviewed scientific journals and a patented inventor.

Articles by Steve Bryson

FDA grants Poseida’s CAR T-cell therapy RMAT status for RRMM

The U.S. Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) status to P-BCMA-ALLO1, Poseida Therapeutics‘ experimental CAR T-cell therapy for adults with relapsed or refractory multiple myeloma (RRMM). The designation is specifically indicated for treating patients who have relapsed or failed to respond after…

Phase 1b trial enrolling to test continuous low-dose lenalidomide

The Gabrail Cancer Center (GCC) in Canton, Ohio is the first site to open in a Phase 1b clinical trial that’s evaluating STAR-LLD, Starton Therapeutics’ investigational continuous delivery of low-dose lenalidomide, in people with multiple myeloma. “I’m thrilled to be the study’s lead investigator and excited about the…

Adding Aphexda helps to collect more stem cells for ASCT in trial

Aphexda (formerly motixafortide), BioLineRx’s experimental add-on therapy, greatly increased the number of blood stem cells collected for autologous stem cell transplants (ASCT), a life-extending treatment for multiple myeloma. While Aphexda generated more stem cells with fewer pre-treatments, it may also help patients who do not generate enough cells…

Elranatamab under FDA priority review for hard-to-treat myeloma

The U.S. Food and Drug Administration (FDA) has granted priority review to Pfizer‘s application of its investigational under-the-skin therapy elranatamab for people with relapsed or refractory multiple myeloma. Priority review is given to therapies that target serious medical conditions that outperform current treatments to make them available to…

Talquetamab for Advanced Multiple Myeloma Up for Approval in EU

Janssen Pharmaceuticals is seeking European Union approval for talquetamab, a subcutaneous (under-the-skin) antibody therapy for hard-to-treat multiple myeloma. The request, in the form of a marketing authorization application to the European Medicines Agency (EMA), will be reviewed under accelerated assessment, which reduces the expected review period from…